Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Squamous Cell Carcinoma of Head and Neck 38Nasopharyngeal Carcinoma 27Lung Neoplasms 26Biliary Tract Neoplasms 24Uterine Cervical Neoplasms 23Esophageal Squamous Cell Carcinoma 20Oropharyngeal Neoplasms 19Cholangiocarcinoma 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 14Ovarian Neoplasms 14Neoplasms 14Neoplasm Metastasis 13Esophageal Neoplasms 13Colorectal Neoplasms 12Carcinoma 12Stomach Neoplasms 10Small Cell Lung Carcinoma 9Carcinoma, Squamous Cell 9Mouth Neoplasms 8Carcinoma, Transitional Cell 8Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Recurrence 6Pancreatic Neoplasms 6Nasopharyngeal Neoplasms 5Gallbladder Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5

Interventions

tislelizumab 1Rutin 1Neoadjuvant Therapy 1Gemcitabine 1Cystectomy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Muscle Invasive Bladder Cancer × Cisplatin × Clear all
NCT06916494 2025-04-10

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

First Affiliated Hospital of Chongqing Medical University

Phase 1 Recruiting
10 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡